OKYO Pharma LtdLSE: OKYO

OKYO Pharma to Participate in 2026 Jefferies...

· Issued by OKYO Pharma Ltd via GlobeNewswire

Summary by 6ix AI

OKYO Pharma Limited, a clinical-stage drug developer working on treatments for neuropathic corneal pain (nerve-related pain in the clear front surface of the eye) and other front-of-eye diseases, will participate in the 2026 Jefferies Global Healthcare Conference in London, United Kingdom, from November 16–19, 2026.

Key details

  • The leadership team will be available for one-on-one investor meetings throughout the conference; investors can arrange meetings through their Jefferies representative.

6ix AI wrote this summary from the release below and checked it against the release.

LONDON and NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will participate at the 2026 Jefferies Global Healthcare Conference in London, United Kingdom taking place from November 16–19, 2026.

The Leadership team will be available for one-on-one investor meetings throughout the conference. Investors interested in arranging a meeting should contact their Jefferies representative.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. Lead candidate, urcosimod for neuropathic corneal pain (NCP), recently announced first patients enrolled in Phase 3 NEPTUNE trial. For more information, please visit www.okyopharma.com and follow us on LinkedIn.

Investor inquiries or meeting requests:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: ir@okyopharma.com

OKYO Pharma Ltd on 6ix

Earlier from OKYO Pharma

All OKYO Pharma news releases